Related Experiment Video
Updated: Jun 23, 2026
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen
Sofie Skovlund Petersen1,2, Stine Møller1,2, Cecilie Slott1,2
1ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 København, Denmark.
Cancers
|March 28, 2024
Summary
This study on pancreatic neuroendocrine neoplasms (pNEN) found overall survival depends on tumor grade. Somatostatin analogues (SSA) showed a median progression-free survival (mPFS) of 28 months, while first-line streptozocin/5-fluorouracil (STZ/5FU) offered a 20-month mPFS.
Area of Science:
- Oncology
- Gastroenterology
- Endocrinology
Background:
- Pancreatic neuroendocrine neoplasms (pNEN) are rare and heterogeneous, leading to treatment decisions based on limited evidence.
- Current treatment strategies for pNEN often rely on expert opinion rather than robust clinical data.
Purpose of the Study:
- To evaluate overall survival (OS), median progression-free survival (mPFS), and identify prognostic factors for common medical treatments in pNEN.
- To provide evidence-based insights into the efficacy of different therapeutic approaches for pNEN.
Main Methods:
- A retrospective single-center study included 192 patients diagnosed and monitored between 2000 and 2020.
- Analysis focused on overall survival, progression-free survival, and the impact of treatment lines and Ki-67 index.
Main Results:
- Median OS varied significantly by grade (G1: 99 months, G2: 62 months, G3: 14 months).
- Somatostatin analogues (SSA) demonstrated an mPFS of 28 months, with no difference based on Ki-67 levels (<10% vs. ≥10%).
- First-line streptozocin/5-fluorouracil (STZ/5FU) achieved an mPFS of 20 months, with WHO grade being an independent risk factor.
Conclusions:
- Overall survival in pNEN is strongly correlated with tumor grade.
- First-line STZ/5FU showed a promising mPFS of 20 months, potentially outperforming historical targeted treatments.
- Peptide receptor radionuclide therapy (PRRT) in G2 pNEN yielded an mPFS comparable to first-line chemotherapy, while high-grade tumors showed limited response to carboplatin/etoposide or temozolomide.
